Clinical Study
The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain
Table 1
Baseline demographics and disease characteristics.
| | | 5-ALA-SFC | Placebo | | | | Result | | Result |
| | Age (years) | 35 | 52.4 (6.51) | 15 | 51.9 (5.07) | | Sex (male) | 35 | 33 (94.3) | 15 | 13 (86.7) | | Fasting plasma glucose (mg/dL) | 33 | 142.3 (21.87) | 15 | 146.4 (31.35) | | Plasma glucose 2 hrs after meal (mg/dL) | 33 | 189.4 (47.96) | 14 | 191.9 (57.97) | | HbA1c (%) | 35 | 7.8 (0.88) | 15 | 8.0 (0.91) | | Total cholesterol (mg/dL) | 34 | 175.6 (36.14) | 15 | 158.8 (31.27) | | LDL (mg/dL) | 34 | 115.4 (33.87) | 15 | 102.0 (26.37) | | HDL (mg/dL) | 34 | 41.1 (10.80) | 15 | 41.5 (10.25) | | Triglycerides (mg/dL) | 34 | 167.0 (89.17) | 15 | 133.7 (55.28) | | Waist (cm) | 34 | 98.6 (21.12) | 15 | 90.3 (17.35) | | BMI (kg/m2) | 35 | 30.8 (5.72) | 15 | 29.3 (5.44) | | Weight (kg) | 35 | 89.8 (17.02) | 15 | 86.6 (18.89) | | Systolic BP (mmHg) | 35 | 137.7 (16.67) | 15 | 131.3 (15.88) | | Diastolic BP (mmHg) | 35 | 80.7 (10.73) | 15 | 76.2 (8.97) | | Heart rate (b/min) | 24 | 78.4 (11.77) | 9 | 72.1 (8.46) |
|
|
All values reported as mean (SD) except sex reported as (%).
|
